Surgical Revascularization versus Percutaneous Coronary Intervention and Optimal Medical Therapy in Diabetic Patients with Multi-Vessel Coronary Artery Disease

Prog Cardiovasc Dis. 2015 Nov-Dec;58(3):306-15. doi: 10.1016/j.pcad.2015.08.005. Epub 2015 Aug 5.

Abstract

Coronary artery disease (CAD) is the leading cause of death in patients with diabetes mellitus (DM). Patients with DM and CAD undergoing revascularization with either a surgical or a percutaneous approach are at higher risk of adverse outcomes and mortality compared with non-DM patients. It is within this background that the optimal choice of revascularization is of critical importance in this high-risk population. The large FREEDOM trial randomized 1900 patients with DM and multivessel CAD to either revascularization with coronary artery by-pass graft (CABG) surgery or percutaneous coronary intervention (PCI). Compared with PCI, CABG significantly reduced the rates of death and myocardial infarction but was associated with a higher risk of stroke. In a real-world setting the decision-making process for the optimal revascularization strategy in these patients is challenging as many clinical factors may influence the decision to either pursue a surgical or a percutaneous revascularization. However, the current consensus is that CABG should be the preferred revascularization strategy in diabetic patients with extensive multivessel CAD.

Keywords: CABG; Coronary artery disease; Diabetes mellitus; PCI; Revascularization.

Publication types

  • Review

MeSH terms

  • Cardiovascular Agents / adverse effects
  • Cardiovascular Agents / economics
  • Cardiovascular Agents / therapeutic use*
  • Coronary Artery Bypass* / adverse effects
  • Coronary Artery Bypass* / economics
  • Coronary Artery Bypass* / mortality
  • Coronary Artery Disease / diagnosis
  • Coronary Artery Disease / economics
  • Coronary Artery Disease / mortality
  • Coronary Artery Disease / therapy*
  • Cost-Benefit Analysis
  • Diabetic Angiopathies / diagnosis
  • Diabetic Angiopathies / economics
  • Diabetic Angiopathies / mortality
  • Diabetic Angiopathies / therapy*
  • Health Care Costs
  • Humans
  • Patient Selection
  • Percutaneous Coronary Intervention* / adverse effects
  • Percutaneous Coronary Intervention* / economics
  • Percutaneous Coronary Intervention* / mortality
  • Quality of Life
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Risk Factors
  • Time Factors
  • Treatment Outcome

Substances

  • Cardiovascular Agents